Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-02-22

AUTHORS

David M. Ross, Tamas Masszi, María Teresa Gómez Casares, Andrzej Hellmann, Jesper Stentoft, Eibhlin Conneally, Valentin Garcia-Gutierrez, Norbert Gattermann, Philipp D. le Coutre, Bruno Martino, Susanne Saussele, Francis J. Giles, Jerald P. Radich, Giuseppe Saglio, Weiping Deng, Nancy Krunic, Véronique Bédoucha, Prashanth Gopalakrishna, Andreas Hochhaus

ABSTRACT

PurposeENESTfreedom is evaluating treatment-free remission (TFR) following frontline nilotinib in patients with chronic myeloid leukemia (CML) in chronic phase. Following our primary analysis at 48 weeks, we here provide an updated 96-week analysis.MethodsAttempting TFR required ≥ 3 years of nilotinib, a molecular response of MR4.5 [BCR-ABL1 ≤ 0.0032% on the International Scale (BCR-ABL1IS)], and sustained deep molecular response (DMR) during a 1-year consolidation phase. Patients restarted nilotinib following loss of major molecular response (MMR; BCR-ABL1IS ≤ 0.1%).ResultsNinety-six weeks after stopping treatment (3.6-year median prior nilotinib duration), 93 of 190 patients (48.9%) remained in TFR. Of 88 patients who restarted nilotinib following loss of MMR, 87 regained MMR and 81 regained MR4.5 by the data cut-off. Ninety-six-week TFR rates were 61.3, 50.0, and 28.6% in patients with low, intermediate, and high Sokal risk scores at diagnosis, respectively. Patients consistently in MR4.5 during consolidation had higher TFR rates (50.6%) than patients with ≥ 1 assessment without MR4.5 during consolidation (35.0%). In a landmark analysis, 96-week TFR rates for patients with MR4.5, MR4 (BCR-ABL1IS ≤ 0.01%) but not MR4.5, and MMR but not MR4 at TFR week 12 were 82.6, 23.1, and 0%, respectively. There were no reports of disease progression or death due to CML; overall adverse event frequency decreased following TFR. Within the follow-up period, TFR did not adversely affect disease outcomes.ConclusionsThese results demonstrate the feasibility and durability of TFR following frontline nilotinib and emphasize the importance of sustained DMR for TFR. More... »

PAGES

945-954

Journal

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00432-018-2604-x

DOI

http://dx.doi.org/10.1007/s00432-018-2604-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1101145018

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29468438


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein-Tyrosine Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrimidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Remission Induction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Haematology, SA Pathology, Room 6E359, Royal Adelaide Hospital, 1 Port Rd, 5000, Adelaide, SA, Australia", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Division of Haematology, SA Pathology, Room 6E359, Royal Adelaide Hospital, 1 Port Rd, 5000, Adelaide, SA, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ross", 
        "givenName": "David M.", 
        "id": "sg:person.01110323637.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110323637.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Semmelweis University, Budapest, Hungary", 
          "id": "http://www.grid.ac/institutes/grid.11804.3c", 
          "name": [
            "Semmelweis University, Budapest, Hungary"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Masszi", 
        "givenName": "Tamas", 
        "id": "sg:person.0751651512.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751651512.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Universitario de Gran Canaria Dr Negr\u00edn, Las Palmas de Gran Canaria, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411250.3", 
          "name": [
            "Hospital Universitario de Gran Canaria Dr Negr\u00edn, Las Palmas de Gran Canaria, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "G\u00f3mez Casares", 
        "givenName": "Mar\u00eda Teresa", 
        "id": "sg:person.0716710447.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716710447.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical University of Gda\u0144sk, Gda\u0144sk, Poland", 
          "id": "http://www.grid.ac/institutes/grid.11451.30", 
          "name": [
            "Medical University of Gda\u0144sk, Gda\u0144sk, Poland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hellmann", 
        "givenName": "Andrzej", 
        "id": "sg:person.01154416326.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154416326.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Aarhus University Hospital, Aarhus, Denmark", 
          "id": "http://www.grid.ac/institutes/grid.154185.c", 
          "name": [
            "Aarhus University Hospital, Aarhus, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stentoft", 
        "givenName": "Jesper", 
        "id": "sg:person.016036621425.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016036621425.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "St James\u2019s Hospital, Dublin, Ireland", 
          "id": "http://www.grid.ac/institutes/grid.416409.e", 
          "name": [
            "St James\u2019s Hospital, Dublin, Ireland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Conneally", 
        "givenName": "Eibhlin", 
        "id": "sg:person.01132647406.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01132647406.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Universitario Ram\u00f3n y Cajal, IRYCIS, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411347.4", 
          "name": [
            "Hospital Universitario Ram\u00f3n y Cajal, IRYCIS, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garcia-Gutierrez", 
        "givenName": "Valentin", 
        "id": "sg:person.01322203274.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322203274.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universit\u00e4tsklinikum D\u00fcsseldorf, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.14778.3d", 
          "name": [
            "Universit\u00e4tsklinikum D\u00fcsseldorf, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gattermann", 
        "givenName": "Norbert", 
        "id": "sg:person.01273447501.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany", 
          "id": "http://www.grid.ac/institutes/grid.6363.0", 
          "name": [
            "Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "le Coutre", 
        "givenName": "Philipp D.", 
        "id": "sg:person.01344447222.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344447222.75"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414504.0", 
          "name": [
            "Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Martino", 
        "givenName": "Bruno", 
        "id": "sg:person.01105522434.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105522434.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "III. Med. Klinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7700.0", 
          "name": [
            "III. Med. Klinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Saussele", 
        "givenName": "Susanne", 
        "id": "sg:person.0611020122.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611020122.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Developmental Therapeutics Consortium, Chicago, IL, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Developmental Therapeutics Consortium, Chicago, IL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Giles", 
        "givenName": "Francis J.", 
        "id": "sg:person.011165370517.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011165370517.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA", 
          "id": "http://www.grid.ac/institutes/grid.270240.3", 
          "name": [
            "Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Radich", 
        "givenName": "Jerald P.", 
        "id": "sg:person.011362420057.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011362420057.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Turin, Orbassano, Italy", 
          "id": "http://www.grid.ac/institutes/grid.7605.4", 
          "name": [
            "University of Turin, Orbassano, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Saglio", 
        "givenName": "Giuseppe", 
        "id": "sg:person.01334477453.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334477453.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA", 
          "id": "http://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Deng", 
        "givenName": "Weiping", 
        "id": "sg:person.01217254625.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217254625.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Institutes for BioMedical Research, Cambridge, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Novartis Institutes for BioMedical Research, Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Krunic", 
        "givenName": "Nancy", 
        "id": "sg:person.016402170507.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016402170507.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Pharma AG, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Pharma AG, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "B\u00e9doucha", 
        "givenName": "V\u00e9ronique", 
        "id": "sg:person.0761205252.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761205252.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Pharma AG, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Pharma AG, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gopalakrishna", 
        "givenName": "Prashanth", 
        "id": "sg:person.0770232473.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770232473.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Abteilung H\u00e4matologie/Onkologie, Universit\u00e4tsklinikum Jena, Jena, Germany", 
          "id": "http://www.grid.ac/institutes/grid.275559.9", 
          "name": [
            "Abteilung H\u00e4matologie/Onkologie, Universit\u00e4tsklinikum Jena, Jena, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hochhaus", 
        "givenName": "Andreas", 
        "id": "sg:person.01064615503.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064615503.48"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/leu.2016.115", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022073613", 
          "https://doi.org/10.1038/leu.2016.115"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00432-016-2159-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050966069", 
          "https://doi.org/10.1007/s00432-016-2159-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2017.63", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083850241", 
          "https://doi.org/10.1038/leu.2017.63"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2016.5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041273297", 
          "https://doi.org/10.1038/leu.2016.5"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-02-22", 
    "datePublishedReg": "2018-02-22", 
    "description": "PurposeENESTfreedom is evaluating treatment-free remission (TFR) following frontline nilotinib in patients with chronic myeloid leukemia (CML) in chronic phase. Following our primary analysis at 48 weeks, we here provide an updated 96-week analysis.MethodsAttempting TFR required\u2009\u2265\u20093\u00a0years of nilotinib, a molecular response of MR4.5 [BCR-ABL1\u2009\u2264\u20090.0032% on the International Scale (BCR-ABL1IS)], and sustained deep molecular response (DMR) during a 1-year consolidation phase. Patients restarted nilotinib following loss of major molecular response (MMR; BCR-ABL1IS\u2009\u2264\u20090.1%).ResultsNinety-six weeks after stopping treatment (3.6-year median prior nilotinib duration), 93 of 190 patients (48.9%) remained in TFR. Of 88 patients who restarted nilotinib following loss of MMR, 87 regained MMR and 81 regained MR4.5 by the data cut-off. Ninety-six-week TFR rates were 61.3, 50.0, and 28.6% in patients with low, intermediate, and high Sokal risk scores at diagnosis, respectively. Patients consistently in MR4.5 during consolidation had higher TFR rates (50.6%) than patients with \u2265\u20091 assessment without MR4.5 during consolidation (35.0%). In a landmark analysis, 96-week TFR rates for patients with MR4.5, MR4 (BCR-ABL1IS\u2009\u2264\u20090.01%) but not MR4.5, and MMR but not MR4 at TFR week 12 were 82.6, 23.1, and 0%, respectively. There were no reports of disease progression or death due to CML; overall adverse event frequency decreased following TFR. Within the follow-up period, TFR did not adversely affect disease outcomes.ConclusionsThese results demonstrate the feasibility and durability of TFR following frontline nilotinib and emphasize the importance of sustained DMR for TFR.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00432-018-2604-x", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1313647", 
        "issn": [
          "0171-5216", 
          "1432-1335"
        ], 
        "name": "Journal of Cancer Research and Clinical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "144"
      }
    ], 
    "keywords": [
      "treatment-free remission", 
      "chronic myeloid leukemia", 
      "deep molecular response", 
      "frontline nilotinib", 
      "TFR rate", 
      "chronic phase", 
      "myeloid leukemia", 
      "high Sokal risk scores", 
      "overall adverse event frequency", 
      "sustained deep molecular response", 
      "durable treatment-free remission", 
      "Sokal risk score", 
      "higher TFR rates", 
      "major molecular response", 
      "adverse event frequency", 
      "molecular response", 
      "loss of MMR", 
      "week 12", 
      "disease progression", 
      "landmark analysis", 
      "disease outcome", 
      "MR4.5", 
      "risk score", 
      "patients", 
      "primary analysis", 
      "nilotinib", 
      "ConclusionsThese results", 
      "remission", 
      "leukemia", 
      "MMR", 
      "weeks", 
      "consolidation phase", 
      "response", 
      "MR4", 
      "diagnosis", 
      "progression", 
      "death", 
      "outcomes", 
      "rate", 
      "treatment", 
      "scores", 
      "event frequency", 
      "report", 
      "loss", 
      "years", 
      "assessment", 
      "period", 
      "analysis", 
      "study", 
      "consolidation", 
      "update", 
      "frequency", 
      "data", 
      "feasibility", 
      "importance", 
      "phase", 
      "results", 
      "durability"
    ], 
    "name": "Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study", 
    "pagination": "945-954", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1101145018"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00432-018-2604-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29468438"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00432-018-2604-x", 
      "https://app.dimensions.ai/details/publication/pub.1101145018"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T17:07", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_780.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00432-018-2604-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00432-018-2604-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00432-018-2604-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00432-018-2604-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00432-018-2604-x'


 

This table displays all metadata directly associated to this object as RDF triples.

370 TRIPLES      21 PREDICATES      102 URIs      90 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00432-018-2604-x schema:about N1cb3ca7738ea4372a1284d7738d073dc
2 N36801b97dbf84d08b9f19ab3e30967cd
3 N3ab19fe09beb4cc9a042b6ca9bd8e5b4
4 N3c135bb0b66c44cb80db48d5403d4ecf
5 N747d4b760b0b4a4abaead50d66464d4d
6 N918279d86770487e8d5dcc3cbc92a8b6
7 N91eaf262be424f0a8cdcae222eb0096c
8 N9700d02da38a448c8ba70aaedc43225f
9 N9c3e72ae6ec14c78a728c0f8e70573f1
10 Nb480faceb1f942af831e990137846d5d
11 Nb77d602429134369917f114e3c47c088
12 Nd0a772f89ba043c8a9ec12b3ffe13f2f
13 Ne1151c1af0654cb48b8078f113036106
14 Ne85dc803e68841d490aa7527e6541d44
15 Nfb635a952ad6488ca40be81f484022f5
16 anzsrc-for:11
17 anzsrc-for:1102
18 schema:author Nd10daa3414a4482197c71c3c455bf0a8
19 schema:citation sg:pub.10.1007/s00432-016-2159-7
20 sg:pub.10.1038/leu.2016.115
21 sg:pub.10.1038/leu.2016.5
22 sg:pub.10.1038/leu.2017.63
23 schema:datePublished 2018-02-22
24 schema:datePublishedReg 2018-02-22
25 schema:description PurposeENESTfreedom is evaluating treatment-free remission (TFR) following frontline nilotinib in patients with chronic myeloid leukemia (CML) in chronic phase. Following our primary analysis at 48 weeks, we here provide an updated 96-week analysis.MethodsAttempting TFR required ≥ 3 years of nilotinib, a molecular response of MR4.5 [BCR-ABL1 ≤ 0.0032% on the International Scale (BCR-ABL1IS)], and sustained deep molecular response (DMR) during a 1-year consolidation phase. Patients restarted nilotinib following loss of major molecular response (MMR; BCR-ABL1IS ≤ 0.1%).ResultsNinety-six weeks after stopping treatment (3.6-year median prior nilotinib duration), 93 of 190 patients (48.9%) remained in TFR. Of 88 patients who restarted nilotinib following loss of MMR, 87 regained MMR and 81 regained MR4.5 by the data cut-off. Ninety-six-week TFR rates were 61.3, 50.0, and 28.6% in patients with low, intermediate, and high Sokal risk scores at diagnosis, respectively. Patients consistently in MR4.5 during consolidation had higher TFR rates (50.6%) than patients with ≥ 1 assessment without MR4.5 during consolidation (35.0%). In a landmark analysis, 96-week TFR rates for patients with MR4.5, MR4 (BCR-ABL1IS ≤ 0.01%) but not MR4.5, and MMR but not MR4 at TFR week 12 were 82.6, 23.1, and 0%, respectively. There were no reports of disease progression or death due to CML; overall adverse event frequency decreased following TFR. Within the follow-up period, TFR did not adversely affect disease outcomes.ConclusionsThese results demonstrate the feasibility and durability of TFR following frontline nilotinib and emphasize the importance of sustained DMR for TFR.
26 schema:genre article
27 schema:isAccessibleForFree true
28 schema:isPartOf N5c3c301a99d64a51ae9f3c53584dca8c
29 Nc2ff315d32014720b23b2a6cbda529a3
30 sg:journal.1313647
31 schema:keywords ConclusionsThese results
32 MMR
33 MR4
34 MR4.5
35 Sokal risk score
36 TFR rate
37 adverse event frequency
38 analysis
39 assessment
40 chronic myeloid leukemia
41 chronic phase
42 consolidation
43 consolidation phase
44 data
45 death
46 deep molecular response
47 diagnosis
48 disease outcome
49 disease progression
50 durability
51 durable treatment-free remission
52 event frequency
53 feasibility
54 frequency
55 frontline nilotinib
56 high Sokal risk scores
57 higher TFR rates
58 importance
59 landmark analysis
60 leukemia
61 loss
62 loss of MMR
63 major molecular response
64 molecular response
65 myeloid leukemia
66 nilotinib
67 outcomes
68 overall adverse event frequency
69 patients
70 period
71 phase
72 primary analysis
73 progression
74 rate
75 remission
76 report
77 response
78 results
79 risk score
80 scores
81 study
82 sustained deep molecular response
83 treatment
84 treatment-free remission
85 update
86 week 12
87 weeks
88 years
89 schema:name Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study
90 schema:pagination 945-954
91 schema:productId N89371d02eeb049dbabcff5cb94d73330
92 Nb981a9dbfb37475092cc7108abb3ec3b
93 Nd228cc19862041c1975ee26d244819c1
94 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101145018
95 https://doi.org/10.1007/s00432-018-2604-x
96 schema:sdDatePublished 2022-08-04T17:07
97 schema:sdLicense https://scigraph.springernature.com/explorer/license/
98 schema:sdPublisher Nc01586e79b7a4ee8851b7f9aa2a14abb
99 schema:url https://doi.org/10.1007/s00432-018-2604-x
100 sgo:license sg:explorer/license/
101 sgo:sdDataset articles
102 rdf:type schema:ScholarlyArticle
103 N1bfb1fac12344870ac6f20218f317e04 rdf:first sg:person.0770232473.03
104 rdf:rest N3278bda933df4776978d45df2922e120
105 N1cb3ca7738ea4372a1284d7738d073dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Leukemia, Myelogenous, Chronic, BCR-ABL Positive
107 rdf:type schema:DefinedTerm
108 N20f946fcd67e45098fe75d3bfc0a77fc rdf:first sg:person.01322203274.19
109 rdf:rest N70cc0e2088fb4a56bda5433cfb439038
110 N22a9eb5de8a2496da34a48451728186a rdf:first sg:person.016036621425.38
111 rdf:rest N5741f246cb024e51939a26711bda7fdc
112 N2a01e5029b7c4a079a04e05ea8827caa rdf:first sg:person.01105522434.09
113 rdf:rest N7b10e7fa91754536a5948c2a4865be38
114 N3278bda933df4776978d45df2922e120 rdf:first sg:person.01064615503.48
115 rdf:rest rdf:nil
116 N36801b97dbf84d08b9f19ab3e30967cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Adult
118 rdf:type schema:DefinedTerm
119 N3ab19fe09beb4cc9a042b6ca9bd8e5b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Middle Aged
121 rdf:type schema:DefinedTerm
122 N3c135bb0b66c44cb80db48d5403d4ecf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Kaplan-Meier Estimate
124 rdf:type schema:DefinedTerm
125 N4a028c7c908c4ab4b0039b1a75a2d36b rdf:first sg:person.0716710447.44
126 rdf:rest Ne7886e174bf448d58df3e9622fa49dca
127 N4fde2e5a3b034f528a72d44a3dad044a rdf:first sg:person.01344447222.75
128 rdf:rest N2a01e5029b7c4a079a04e05ea8827caa
129 N5741f246cb024e51939a26711bda7fdc rdf:first sg:person.01132647406.49
130 rdf:rest N20f946fcd67e45098fe75d3bfc0a77fc
131 N5c3c301a99d64a51ae9f3c53584dca8c schema:volumeNumber 144
132 rdf:type schema:PublicationVolume
133 N5e59ca807c9c4fe594f1dc1df1491aff rdf:first sg:person.011362420057.85
134 rdf:rest Nfcd1fe6ffa0e4f369dfa04b18bc0622a
135 N70cc0e2088fb4a56bda5433cfb439038 rdf:first sg:person.01273447501.34
136 rdf:rest N4fde2e5a3b034f528a72d44a3dad044a
137 N747d4b760b0b4a4abaead50d66464d4d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Time Factors
139 rdf:type schema:DefinedTerm
140 N7b10e7fa91754536a5948c2a4865be38 rdf:first sg:person.0611020122.69
141 rdf:rest N8d5f497d74d94aee8ab0fd4fd500c416
142 N89371d02eeb049dbabcff5cb94d73330 schema:name pubmed_id
143 schema:value 29468438
144 rdf:type schema:PropertyValue
145 N8d5f497d74d94aee8ab0fd4fd500c416 rdf:first sg:person.011165370517.24
146 rdf:rest N5e59ca807c9c4fe594f1dc1df1491aff
147 N918279d86770487e8d5dcc3cbc92a8b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Male
149 rdf:type schema:DefinedTerm
150 N91eaf262be424f0a8cdcae222eb0096c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Aged
152 rdf:type schema:DefinedTerm
153 N9700d02da38a448c8ba70aaedc43225f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Young Adult
155 rdf:type schema:DefinedTerm
156 N9c3e72ae6ec14c78a728c0f8e70573f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Remission Induction
158 rdf:type schema:DefinedTerm
159 Na981b2a0297a4be8a79745d4a2a70e16 rdf:first sg:person.0751651512.21
160 rdf:rest N4a028c7c908c4ab4b0039b1a75a2d36b
161 Nb480faceb1f942af831e990137846d5d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Female
163 rdf:type schema:DefinedTerm
164 Nb77d602429134369917f114e3c47c088 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Pyrimidines
166 rdf:type schema:DefinedTerm
167 Nb981a9dbfb37475092cc7108abb3ec3b schema:name dimensions_id
168 schema:value pub.1101145018
169 rdf:type schema:PropertyValue
170 Nc01586e79b7a4ee8851b7f9aa2a14abb schema:name Springer Nature - SN SciGraph project
171 rdf:type schema:Organization
172 Nc2ff315d32014720b23b2a6cbda529a3 schema:issueNumber 5
173 rdf:type schema:PublicationIssue
174 Nd0a772f89ba043c8a9ec12b3ffe13f2f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Aged, 80 and over
176 rdf:type schema:DefinedTerm
177 Nd10daa3414a4482197c71c3c455bf0a8 rdf:first sg:person.01110323637.14
178 rdf:rest Na981b2a0297a4be8a79745d4a2a70e16
179 Nd228cc19862041c1975ee26d244819c1 schema:name doi
180 schema:value 10.1007/s00432-018-2604-x
181 rdf:type schema:PropertyValue
182 Nd30d15d01b00448197a98d2744dff98b rdf:first sg:person.016402170507.13
183 rdf:rest Nfe23495871bc46ffa6012b2c69c1e564
184 Ne1151c1af0654cb48b8078f113036106 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Protein-Tyrosine Kinases
186 rdf:type schema:DefinedTerm
187 Ne163821da5e4487fb067ebb38904a44a rdf:first sg:person.01217254625.41
188 rdf:rest Nd30d15d01b00448197a98d2744dff98b
189 Ne7886e174bf448d58df3e9622fa49dca rdf:first sg:person.01154416326.31
190 rdf:rest N22a9eb5de8a2496da34a48451728186a
191 Ne85dc803e68841d490aa7527e6541d44 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Humans
193 rdf:type schema:DefinedTerm
194 Nfb635a952ad6488ca40be81f484022f5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Treatment Outcome
196 rdf:type schema:DefinedTerm
197 Nfcd1fe6ffa0e4f369dfa04b18bc0622a rdf:first sg:person.01334477453.06
198 rdf:rest Ne163821da5e4487fb067ebb38904a44a
199 Nfe23495871bc46ffa6012b2c69c1e564 rdf:first sg:person.0761205252.14
200 rdf:rest N1bfb1fac12344870ac6f20218f317e04
201 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
202 schema:name Medical and Health Sciences
203 rdf:type schema:DefinedTerm
204 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
205 schema:name Cardiorespiratory Medicine and Haematology
206 rdf:type schema:DefinedTerm
207 sg:journal.1313647 schema:issn 0171-5216
208 1432-1335
209 schema:name Journal of Cancer Research and Clinical Oncology
210 schema:publisher Springer Nature
211 rdf:type schema:Periodical
212 sg:person.01064615503.48 schema:affiliation grid-institutes:grid.275559.9
213 schema:familyName Hochhaus
214 schema:givenName Andreas
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064615503.48
216 rdf:type schema:Person
217 sg:person.01105522434.09 schema:affiliation grid-institutes:grid.414504.0
218 schema:familyName Martino
219 schema:givenName Bruno
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105522434.09
221 rdf:type schema:Person
222 sg:person.01110323637.14 schema:affiliation grid-institutes:None
223 schema:familyName Ross
224 schema:givenName David M.
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110323637.14
226 rdf:type schema:Person
227 sg:person.011165370517.24 schema:affiliation grid-institutes:None
228 schema:familyName Giles
229 schema:givenName Francis J.
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011165370517.24
231 rdf:type schema:Person
232 sg:person.01132647406.49 schema:affiliation grid-institutes:grid.416409.e
233 schema:familyName Conneally
234 schema:givenName Eibhlin
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01132647406.49
236 rdf:type schema:Person
237 sg:person.011362420057.85 schema:affiliation grid-institutes:grid.270240.3
238 schema:familyName Radich
239 schema:givenName Jerald P.
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011362420057.85
241 rdf:type schema:Person
242 sg:person.01154416326.31 schema:affiliation grid-institutes:grid.11451.30
243 schema:familyName Hellmann
244 schema:givenName Andrzej
245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154416326.31
246 rdf:type schema:Person
247 sg:person.01217254625.41 schema:affiliation grid-institutes:grid.418424.f
248 schema:familyName Deng
249 schema:givenName Weiping
250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217254625.41
251 rdf:type schema:Person
252 sg:person.01273447501.34 schema:affiliation grid-institutes:grid.14778.3d
253 schema:familyName Gattermann
254 schema:givenName Norbert
255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34
256 rdf:type schema:Person
257 sg:person.01322203274.19 schema:affiliation grid-institutes:grid.411347.4
258 schema:familyName Garcia-Gutierrez
259 schema:givenName Valentin
260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322203274.19
261 rdf:type schema:Person
262 sg:person.01334477453.06 schema:affiliation grid-institutes:grid.7605.4
263 schema:familyName Saglio
264 schema:givenName Giuseppe
265 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334477453.06
266 rdf:type schema:Person
267 sg:person.01344447222.75 schema:affiliation grid-institutes:grid.6363.0
268 schema:familyName le Coutre
269 schema:givenName Philipp D.
270 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344447222.75
271 rdf:type schema:Person
272 sg:person.016036621425.38 schema:affiliation grid-institutes:grid.154185.c
273 schema:familyName Stentoft
274 schema:givenName Jesper
275 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016036621425.38
276 rdf:type schema:Person
277 sg:person.016402170507.13 schema:affiliation grid-institutes:grid.418424.f
278 schema:familyName Krunic
279 schema:givenName Nancy
280 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016402170507.13
281 rdf:type schema:Person
282 sg:person.0611020122.69 schema:affiliation grid-institutes:grid.7700.0
283 schema:familyName Saussele
284 schema:givenName Susanne
285 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611020122.69
286 rdf:type schema:Person
287 sg:person.0716710447.44 schema:affiliation grid-institutes:grid.411250.3
288 schema:familyName Gómez Casares
289 schema:givenName María Teresa
290 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716710447.44
291 rdf:type schema:Person
292 sg:person.0751651512.21 schema:affiliation grid-institutes:grid.11804.3c
293 schema:familyName Masszi
294 schema:givenName Tamas
295 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751651512.21
296 rdf:type schema:Person
297 sg:person.0761205252.14 schema:affiliation grid-institutes:grid.419481.1
298 schema:familyName Bédoucha
299 schema:givenName Véronique
300 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761205252.14
301 rdf:type schema:Person
302 sg:person.0770232473.03 schema:affiliation grid-institutes:grid.419481.1
303 schema:familyName Gopalakrishna
304 schema:givenName Prashanth
305 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770232473.03
306 rdf:type schema:Person
307 sg:pub.10.1007/s00432-016-2159-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050966069
308 https://doi.org/10.1007/s00432-016-2159-7
309 rdf:type schema:CreativeWork
310 sg:pub.10.1038/leu.2016.115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022073613
311 https://doi.org/10.1038/leu.2016.115
312 rdf:type schema:CreativeWork
313 sg:pub.10.1038/leu.2016.5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041273297
314 https://doi.org/10.1038/leu.2016.5
315 rdf:type schema:CreativeWork
316 sg:pub.10.1038/leu.2017.63 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083850241
317 https://doi.org/10.1038/leu.2017.63
318 rdf:type schema:CreativeWork
319 grid-institutes:None schema:alternateName Developmental Therapeutics Consortium, Chicago, IL, USA
320 Division of Haematology, SA Pathology, Room 6E359, Royal Adelaide Hospital, 1 Port Rd, 5000, Adelaide, SA, Australia
321 schema:name Developmental Therapeutics Consortium, Chicago, IL, USA
322 Division of Haematology, SA Pathology, Room 6E359, Royal Adelaide Hospital, 1 Port Rd, 5000, Adelaide, SA, Australia
323 rdf:type schema:Organization
324 grid-institutes:grid.11451.30 schema:alternateName Medical University of Gdańsk, Gdańsk, Poland
325 schema:name Medical University of Gdańsk, Gdańsk, Poland
326 rdf:type schema:Organization
327 grid-institutes:grid.11804.3c schema:alternateName Semmelweis University, Budapest, Hungary
328 schema:name Semmelweis University, Budapest, Hungary
329 rdf:type schema:Organization
330 grid-institutes:grid.14778.3d schema:alternateName Universitätsklinikum Düsseldorf, Düsseldorf, Germany
331 schema:name Universitätsklinikum Düsseldorf, Düsseldorf, Germany
332 rdf:type schema:Organization
333 grid-institutes:grid.154185.c schema:alternateName Aarhus University Hospital, Aarhus, Denmark
334 schema:name Aarhus University Hospital, Aarhus, Denmark
335 rdf:type schema:Organization
336 grid-institutes:grid.270240.3 schema:alternateName Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
337 schema:name Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
338 rdf:type schema:Organization
339 grid-institutes:grid.275559.9 schema:alternateName Abteilung Hämatologie/Onkologie, Universitätsklinikum Jena, Jena, Germany
340 schema:name Abteilung Hämatologie/Onkologie, Universitätsklinikum Jena, Jena, Germany
341 rdf:type schema:Organization
342 grid-institutes:grid.411250.3 schema:alternateName Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain
343 schema:name Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain
344 rdf:type schema:Organization
345 grid-institutes:grid.411347.4 schema:alternateName Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain
346 schema:name Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain
347 rdf:type schema:Organization
348 grid-institutes:grid.414504.0 schema:alternateName Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
349 schema:name Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
350 rdf:type schema:Organization
351 grid-institutes:grid.416409.e schema:alternateName St James’s Hospital, Dublin, Ireland
352 schema:name St James’s Hospital, Dublin, Ireland
353 rdf:type schema:Organization
354 grid-institutes:grid.418424.f schema:alternateName Novartis Institutes for BioMedical Research, Cambridge, MA, USA
355 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
356 schema:name Novartis Institutes for BioMedical Research, Cambridge, MA, USA
357 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
358 rdf:type schema:Organization
359 grid-institutes:grid.419481.1 schema:alternateName Novartis Pharma AG, Basel, Switzerland
360 schema:name Novartis Pharma AG, Basel, Switzerland
361 rdf:type schema:Organization
362 grid-institutes:grid.6363.0 schema:alternateName Charité-Universitätsmedizin Berlin, Berlin, Germany
363 schema:name Charité-Universitätsmedizin Berlin, Berlin, Germany
364 rdf:type schema:Organization
365 grid-institutes:grid.7605.4 schema:alternateName University of Turin, Orbassano, Italy
366 schema:name University of Turin, Orbassano, Italy
367 rdf:type schema:Organization
368 grid-institutes:grid.7700.0 schema:alternateName III. Med. Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
369 schema:name III. Med. Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
370 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...